Staphylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients

Journal of Cystic Fibrosis

Volumn 10, Issue 5, 2011, Pages 377-382

  Filleron, Anne ^a   Chiron, Raphaël ^a   Reverdy, Marie Elisabeth ^b   Jean Pierre, Hélène ^a,c   Dumitrescu, Oana ^b   Aleyrangues, Linda ^a   Counil, François ^a   Jumas Bilak, Estelle ^c   Marchandin, Hélène ^a,c  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

Cystic fibrosis; GISA; Glycopeptides; Resistance; Staphylococcus aureus

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANATE POTASSIUM PLUS TICARCILLIN; COTRIMOXAZOLE; FUSIDIC ACID; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; NEOMYCIN; PRISTINAMYCIN; RIFAMPICIN; SULFAMETHOXAZOLE; TEICOPLANIN; TOBRAMYCIN; TRIMETHOPRIM;

ADOLESCENT; ADULT; AEROSOL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLUS FUMIGATUS; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATION; BODY MASS; CHILD; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROTOMY; GENOTYPE; GLYCOPEPTIDE INTERMEDIATE STAPHYLOCOCCUS AUREUS; GLYCOPEPTIDE INTERMEDIATE STAPHYLOCOCCUS AUREUS INFECTION; HUMAN; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MULTIPLE CYCLE TREATMENT; OXYGEN THERAPY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT OUTCOME;

ACETAMIDES; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; CHILD; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; YOUNG ADULT;

EID: 80052486420     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.05.001     Document Type: Article

References (24)

1. Filleron A, Chiron R, Jean-Pierre H, Reverdy ME, Aleyrangues L, Counil F, Jumas-Bilak E, Marchandin H. Staphylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients. 32nd European Cystic Fibrosis Society Conference, Brest, France, 10-13 June 2009.
2. Denis O., Nonhoff C., Byl B., Knoop C., Bobin-Dubreux S., Struelens M.J. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J Antimicrob Chemother 2002, 50:383-391.
3. Dumitrescu O, Reverdy ME, Bes M, et al. Étude phénotypique et génotypique de 9 souches de Staphylococcus aureus de sensibilité diminuée aux glycopeptides, isolées chez des enfants atteints de mucoviscidose. 29th Réunion Interdisciplinaire de Chimiothérapie Anti-infectieuse, Paris, France, 3-4 December 2009.
4. Cafiso V., Bertuccio T., Spina D., et al. Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2010, 29:1277-1285.
5. Hiramatsu K., Aritaka N., Hanaki H., et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997, 350:1670-1673.
6. Bobin-Dubreux S., Reverdy M.E., Nervi C., et al. Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative. Antimicrob Agents Chemother 2001, 45:349-352.
7. Enright M.C., Day N.P., Davies C.E., Peacock S.J., Spratt B.G. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000, 38:1008-1015.
8. Al-Obeid S., Haddad Q., Cherkaoui A., Schrenzel J., François P. First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia. J Clin Microbiol 2010, 48:2199-2220.
9. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb Mortal Wkly Rep 1997, 46:765-766. Centers for Disease Control and Prevention (CDC.
10. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997, 40:135-136.
11. Rong S.L., Leonard S.N. Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance. Ann Pharmacother 2010, 44:844-850.
12. Conly J.M., Johnston B.L. VISA, hetero-VISA and VRSA: the end of the vancomycin era?. Can J Infect Dis 2002, 13:282-284.
13. Fridkin S.K., Hageman J., McDougal L.K., et al. Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003, 36:429-439.
14. Liu C., Chambers H.F. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003, 47:3040-3045.
15. Macfarlane M., Leavy A., McCaughan J., Fair R., Reid A.J. Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J Hosp Infect 2007, 65:231-236.
16. Pillai S.K., Wennersten C., Venkataraman L., Eliopoulos G.M., Moellering R.C., Karchmer A.W. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis 2009, 49:1169-1174.
17. Garnier F., Chainier D., Walsh T., et al. A 1year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother 2006, 57:146-149.
18. Howe R.A., Monk A., Wootton M., Walsh T.R., Enright M.C. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis 2004, 10:855-857.
19. Noto M.J., Fox P.M., Archer G.L. Spontaneous deletion of the methicillin resistance determinant, mecA, partially compensates for the fitness cost associated with high-level vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2008, 52:1221-1229.
20. Liñares J. The VISA/GISA problem: therapeutic implications. Clin Microbiol Infect 2001, 7(Suppl. 4):8-15.
21. Ferrin M., Zuckerman J.B., Meagher A., Blumberg E.A. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr Pulmonol 2002, 33:221-223.
22. Gales A.C., Sader H.S., Andrade S.S., Lutz L., Machado A., Barth A.L. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 2006, 27:300-302.
23. Zander J., Besier S., Saum S.H., et al. Influence of dTMP on the phenotypic appearance and intracellular persistence of Staphylococcus aureus. Infect Immun 2008, 76:1333-1339.
24. Besier S., Smaczny C., von Mallinckrodt C., et al. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol 2007, 45:168-172.